University of Iowa

uiowa.edu

Total trials

272

Active

45

Phase 3

8

Total enrollment

67,713

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 19 of 19 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Metronidazole 0.75% Topical Gel1
Metronidazole 0.75% Topical Cream1
Intravenous administered opioid1
Epidural administered opioid1
Salsalate Oral2
Dostarlimab2
Psilocybin1
Fish Oil Concentrate, 1000 Mg Oral1
Lutetium Lu 177 dotatate therapy1
Doxycycline Hyclate1
Ketamine2
Terazosin1
Ascorbate1
Acetylcholine1
Terazosine1
Thoracolumbar Interfascial Plane (TLIP) Block of bupivacaine1
Salsalate 750 MG Oral Tablet [DISALCID]1
IV adenosine1
IV diltiazem1

Next readouts

  • 2023-03-01
  • 2025-03-18
  • 2025-08-12
  • 2026-06
  • 2026-07
  • 2026-12-30
  • 2026-12-31
  • 2026-12-31
  • 2027-02-01
  • 2027-05-01

Top conditions

  • Healthy14
  • Knee Osteoarthritis10
  • Obesity6
  • Depression6
  • Hypertension5
  • Multiple Sclerosis5
  • Cardiovascular Diseases4
  • Adult ALL3

Frequently asked questions about University of Iowa

How many clinical trials does University of Iowa have on ClinicalTrials.gov?
University of Iowa is listed as the lead sponsor on 272 clinical trials in ClinicalTrials.gov, 45 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Iowa's trials are in Phase 3?
8 of University of Iowa's trials are in Phase 3, spread across 19 active drug programs.
What therapeutic areas does University of Iowa focus on?
University of Iowa's most-studied conditions on ClinicalTrials.gov are Healthy, Knee Osteoarthritis, Obesity, Depression, Hypertension.
When are University of Iowa's next clinical trial readouts?
University of Iowa has 10 upcoming primary-completion readouts tracked here; the soonest is “Target Engagement of Terazosin in Healthy Adults”, expected around 2023-03-01.